Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone add-on therapy for recent-onset psychotic disorder
NL-OMON38677Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizophreniform disorder, schizoaffective disorder and 1 more comparing Prednisolone add-on with Placebo add-on (2 arms). Primary endpoint: Change in PANSS total score. Planned start Sep 2013; status: withdrawn.
02
Drugs
prednisolone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON38677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38677.